Figure 3.

The approach to treatment for patients with acute-on-chronic liver failure (ACLF) with bacterial infections. Empirical anti-infective treatments should be based on the severity of infection, the risk factors for multidrug resistant (MDR) bacteria and epidemiological characteristics. BIs – bacterial infections; CAP – community-acquired infection; MDR – multidrug resistant; MRSA – methicillin-resistant Staphylococcus aureus; VSE – vancomycin-sensitive Enterococci; VRE – vancomycin-resistant Enterococci.